drugset / Trial / NCT03917069
Nab-PCE vs PC for MM After Failure of Anti-PD-1
RandomizedCrossoverOpen-labelTreatment
Summary
This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin * Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin * endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.
Timeline
- Start
- 2019-03-23
- Primary completion
- 2021-09-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 15 mg | — |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Comparator | Carboplatin | Small molecule | — | — |